Compare MICC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MICC | BIO |
|---|---|---|
| Founded | 2025 | 1952 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 10.3B |
| IPO Year | 2025 | 1994 |
| Metric | MICC | BIO |
|---|---|---|
| Price | $19.74 | $360.58 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 4 | 3 |
| Target Price | $19.77 | ★ $356.67 |
| AVG Volume (30 Days) | ★ 795.9K | 232.9K |
| Earning Date | 02-12-2027 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | N/A | ★ 11.25 |
| Revenue | N/A | ★ $2,583,200,000.00 |
| Revenue This Year | $6.59 | N/A |
| Revenue Next Year | $4.61 | $1.86 |
| P/E Ratio | ★ $28.55 | $32.60 |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $12.94 | $236.73 |
| 52 Week High | $20.69 | $396.23 |
| Indicator | MICC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 42.05 |
| Support Level | $19.00 | $354.27 |
| Resistance Level | $20.00 | $392.10 |
| Average True Range (ATR) | 0.33 | 12.87 |
| MACD | -0.01 | -1.48 |
| Stochastic Oscillator | 60.33 | 18.57 |
The Magnum Ice Cream Co., spun off from Unilever, manufactures and sells a broad portfolio of ice cream brands. The company is a global category leader, operating in 80 countries with around 21% market share. TMICC owns four of the world's five largest ice cream brands: Heartbrand (an umbrella brand with numerous well-known subbrands, which constitutes around 35% of sales), Magnum (23%), Ben & Jerry's (14%), and Cornetto (9%). The business generates about 65% of its revenue in developed markets, with the balance coming from emerging markets.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.